Agomelatine treatment with adolescents with ADHD.
OBJECTIVE
Antidepressants, in particular Atomextine, along with stimulants have demonstrated benefit in the treatment of ADHD. Agomelatine is a new antidepressant with additional affinities to the melatonergic system. As ADHD has been associated with sleep disorders, it is assumed that Agomelatiine might serve as a therapeutic alternative to treat patients with the ADHD refractory to first line medications.


METHODS
Ten late adolescents were evaluated in a placebo controlled manner.


RESULTS
Agomelatine's effect was superior to that of placebo but appeared to be less than that of first line medications such as methylphenidate.


CONCLUSIONS
Agomelatine may be a useful second line medication for individuals with ADHD, particularly if they suffer from additional sleep disorders.
Department of Child and Adolescent Psychiatry, Saechsisches Krankenhaus D-08228, Rodewisch, Germany. helmutniederhofer@yahoo.de
Helmut
H
Niederhofer
D000081:Acetamides / Q000627:therapeutic use*; D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome; D055815:Young Adult; D009281:Naphthalenes
D000081:Acetamides; D006993:Hypnotics and Sedatives; C084711:agomelatine; D009281:Naphthalenes